GSA Capital Partners LLP Invests $505,000 in Myriad Genetics, Inc. (NASDAQ:MYGN)

GSA Capital Partners LLP purchased a new position in Myriad Genetics, Inc. (NASDAQ:MYGN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 18,420 shares of the company’s stock, valued at approximately $505,000.

A number of other large investors have also recently made changes to their positions in MYGN. Vanguard Group Inc. grew its position in Myriad Genetics by 0.8% during the first quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company’s stock valued at $213,961,000 after buying an additional 81,475 shares during the period. Earnest Partners LLC grew its position in Myriad Genetics by 3.5% during the second quarter. Earnest Partners LLC now owns 4,072,018 shares of the company’s stock valued at $99,602,000 after buying an additional 138,960 shares during the period. Dimensional Fund Advisors LP grew its position in Myriad Genetics by 2.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,776,959 shares of the company’s stock valued at $67,924,000 after buying an additional 75,445 shares during the period. Sei Investments Co. grew its position in Myriad Genetics by 5.4% during the second quarter. Sei Investments Co. now owns 2,417,192 shares of the company’s stock valued at $59,125,000 after buying an additional 124,007 shares during the period. Finally, Disciplined Growth Investors Inc. MN grew its position in Myriad Genetics by 0.5% during the second quarter. Disciplined Growth Investors Inc. MN now owns 2,087,328 shares of the company’s stock valued at $51,056,000 after buying an additional 10,035 shares during the period. 99.02% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Myriad Genetics news, Director Colleen F. Reitan sold 46,012 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the completion of the transaction, the director now owns 42,533 shares in the company, valued at $1,188,797.35. This trade represents a 51.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction on Friday, October 11th. The shares were sold at an average price of $22.93, for a total transaction of $343,950.00. Following the transaction, the chief executive officer now owns 962,378 shares of the company’s stock, valued at $22,067,327.54. This trade represents a 1.53 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,012 shares of company stock worth $1,900,485. 2.10% of the stock is owned by insiders.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $15.00 on Wednesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.73 and a current ratio of 1.90. The firm has a fifty day moving average price of $22.95 and a 200 day moving average price of $24.61. Myriad Genetics, Inc. has a fifty-two week low of $14.77 and a fifty-two week high of $29.30. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -11.54 and a beta of 1.93.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MYGN. Wells Fargo & Company began coverage on shares of Myriad Genetics in a research report on Tuesday, August 27th. They set an “overweight” rating and a $35.00 target price for the company. Scotiabank boosted their target price on shares of Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Tuesday, August 13th. Morgan Stanley cut their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a research report on Monday. TD Cowen increased their price objective on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Myriad Genetics from $17.00 to $20.00 and gave the stock an “underweight” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.36.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.